Andrew Duker, MD
Neurology · Cincinnati, OHNPI 1780623603
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $2,115 of the $2,808 with a category attached, or 75.3%. Kyowa Kirin, Inc. accounts for 75.3% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2020 at $2,151 and has fallen 96.4% since, to $78 in 2025.
Across 15 payments — averaging $187.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Kyowa Kirin, Inc.$2K
- Abbott$152
- Insightec,inc$146
- Teva Pharmaceuticals USA, Inc.$111
- Genentech USA, Inc.$91
- AbbVie$69
- plus $124 from 4 others
Across 38 payments — averaging $16,409 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sage Therapeutics, LLC$547K
- Boston Scientific$46K
- Acorda Therapeutics, Inc$24K
- Neurocrine Biosciences, Inc.$6K
What the payments were for
- Consulting fees$2,11575%
- Food & beverage$58221%
- Education$1114%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Kyowa Kirin, Inc. | 1 | $2,115 |
| Abbott | 2 | $152 |
| Insightec,inc | 1 | $146 |
| Teva Pharmaceuticals USA, Inc. | 1 | $111 |
| Genentech USA, Inc. | 1 | $91 |
| AbbVie | 3 | $69 |
| Ipsen Biopharmaceuticals, Inc | 1 | $49 |
| Boston Scientific | 2 | $26 |
| Amneal Pharmaceuticals LLC | 2 | $26 |
| Revance Therapeutics, Inc. | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,808 in reported general payments places this provider in the 60th percentile of 702 neurology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RytaryCarbidopa/Levodopa | 360 | $579,087 |
| NuplazidPimavanserin Tartrate | 52 | $329,817 |
| IngrezzaValbenazine Tosylate | 40 | $320,068 |
| NortheraDroxidopa | 12 | $258,944 |
| AustedoDeutetrabenazine | 43 | $253,088 |
| GocovriAmantadine Hcl | 26 | $97,877 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 919 | $52,172 |
| NuedextaDextromethorphan Hbr/Quinidine | 21 | $44,477 |
| Droxidopa | 14 | $19,993 |
| Rivastigmine | 63 | $17,516 |
| Rasagiline Mesylate | 54 | $12,601 |
| Tetrabenazine | 29 | $12,065 |
| AmantadineAmantadine Hcl | 179 | $10,481 |
| Entacapone | 58 | $8,227 |
| Midodrine Hcl | 135 | $7,640 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Amneal Pharmaceuticals LLCRytary | $26 | $579,087360 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $111 | $253,08843 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 702 neurology providers in Ohio.
Other neurology in Cincinnati
- Aram ZabetiCincinnati$1.6M
- Brandon ForemanCincinnati$385K
- Alberto EspayCincinnati$351K
- Michael PriviteraCincinnati$243K
- Brian MoseleyCincinnati$220K
- Zainab ContractorCincinnati$181K
- Reena ShahCincinnati$180K
- Marsha SmithCincinnati$178K
- David SchmerlerCincinnati$162K
- Hani KushlafCincinnati$115K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.